Subsequent Events	6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On July 29, 2026, the Company entered into a settlement agreement and release (the “Settlement Agreement”) with Alexion, resolving a commercial dispute regarding U.S. royalties on Ultomiris® (ravulizumab-cwvz). As previously disclosed, in March 2026, Alexion notified the Company of its position that no additional royalties were owed on U.S. sales of Ultomiris and that it did not intend to make further payments related to U.S. sales. The Settlement Agreement fully and finally resolves this dispute. Pursuant to the Settlement Agreement, the Company will receive an aggregate of $105.0 million from Alexion, payable in two equal installments of $52.5 million: the first payment is anticipated to be received in August 2026, and the second payment is due following the one-year anniversary of the date of the Settlement Agreement. Following the settlement, Alexion has no further obligation to pay royalties on U.S. sales of Ultomiris. The Settlement Agreement does not affect the Company’s right to receive royalties on ex-U.S. sales of Ultomiris under the existing terms of the Alexion Agreement, as amended.

Subsequent Events

6 Months Ended

Jun. 30, 2026

On July 29, 2026, the Company entered into a settlement agreement and release (the “Settlement Agreement”) with Alexion, resolving a commercial dispute regarding U.S. royalties on Ultomiris® (ravulizumab-cwvz).

As previously disclosed, in March 2026, Alexion notified the Company of its position that no additional royalties were owed on U.S. sales of Ultomiris and that it did not intend to make further payments related to U.S. sales. The Settlement Agreement fully and finally resolves this dispute.

Pursuant to the Settlement Agreement, the Company will receive an aggregate of $105.0 million from Alexion, payable in two equal installments of $52.5 million: the first payment is anticipated to be received in August 2026, and the second payment is due following the one-year anniversary of the date of the Settlement Agreement. Following the settlement, Alexion has no further obligation to pay royalties on U.S. sales of Ultomiris. The Settlement Agreement does not affect the Company’s right to receive royalties on ex-U.S. sales of Ultomiris under the existing terms of the Alexion Agreement, as amended.